-
IR-1061: Molecular Design for NIR-II Imaging
2026-09-09
IR-1061 is a near infrared fluorescent dye whose imaging performance depends not only on its spectrum, but also on polymer microenvironment, aggregation, and formulation stability. This article translates mechanistic findings from PLA encapsulation research into practical assay-design decisions for reproducible deep-tissue optical imaging.
-
Substance P (B6620) for Reliable Cell Assays
2026-09-09
This scenario-based guide explains how Substance P (SKU B6620) can be incorporated into cell viability, proliferation, and cytotoxicity workflows while controlling formulation, handling, and data-interpretation variables. It connects NK-1 biology with practical assay design and evidence-based spectral quality control.
-
Topotecan Pharmacology and Clinical Evidence
2026-09-08
The reference review established topotecan as a water-soluble topoisomerase I inhibitor with a distinct DNA-damage mechanism, characteristic lactone chemistry, and clinically important hematologic toxicity. Its synthesis of pharmacology, early clinical schedules, and phase II–III evidence provides a useful framework for interpreting apoptosis induction in cancer cells and designing translational cancer research workflows.
-
Balsalazide disodium in Inflammation Research
2026-09-08
Balsalazide disodium supports colon-focused inflammation research through bacterial activation of a 5-aminosalicylic acid prodrug and a water-compatible formulation. Its most distinctive applied use is the transition from routine immunology assays to a radiolabeled ulcerative colitis imaging workflow, with practical controls for solubility, labeling, stability, and biodistribution.
-
Decitabine Primes Anti–PD-1 via Progenitor Tex
2026-09-07
Li et al. show that low-dose decitabine strengthens anti–PD-1 therapy by expanding and preserving proliferative CD8+ progenitor exhausted T cells rather than merely increasing short-term effector activity. The study connects this phenotype to sustained JunD and JNK/AP-1 signaling, offering a mechanistic framework for epigenetic priming in tumor immunotherapy.
-
Bardoxolone Methyl: Redox-Aware Assays
2026-09-07
Bardoxolone methyl, also known as CDDO methyl ester, is examined here as a redox-perturbation tool for mechanistic assay design. The article connects Nrf2 and NF-kB biology with thioredoxin-controlled nucleotide metabolism, emphasizing controls that distinguish pathway activation from nonspecific cytotoxicity.
-
Central Control of Opioid Hypersensitivity
2026-09-05
Yin et al. identify a brain-to-spinal opioid pathway linking lateral parabrachial MOR neurons, hypothalamic dynorphin neurons, and spinal KOR-expressing GABAergic neurons to morphine-induced mechanical hypersensitivity and analgesic tolerance. The study separates mechanical from thermal opioid side effects and provides a circuit framework for testing how central gate control contributes to opioid-related pain amplification.
-
Anti-inflammatory and Anti-angiogenic Airway Stents
2026-09-04
Zhao et al. developed PAGL, an electrospun airway stent combining anlotinib hydrochloride with silver nanoparticles to address infection, inflammation, angiogenesis, and fibroblast activation in tracheal in-stent restenosis. In vitro, animal, and RNA-sequencing results support a multifunctional strategy, although clinical translation and component-specific mechanisms remain to be established.
-
Cyclophosphamide: Designing Better Research Models
2026-09-04
Cyclophosphamide is an alkylating chemotherapeutic agent whose bioactivation, DNA damage, and immune effects can reshape experimental outcomes. This guide connects cancer research, immune conditioning, and PK/PD-informed model design while clarifying what neutropenic infection data can—and cannot—tell investigators.
-
Western Secondary Antibody Dilution Buffer for NHE1 Blots
2026-09-03
Build more consistent Western blots for the NHE1–Olfr2–calcium inflammatory axis with a stabilizing diluent designed for secondary antibodies. The workflow emphasizes controlled antibody reuse, signal-to-background checks, and assay decisions tailored to macrophage atherosclerosis research.
-
Ruxolitinib Phosphate: From JAK Signals to Cell Fate
2026-09-03
Ruxolitinib phosphate (INCB018424) is more than a selective JAK1/JAK2 research tool. Evidence in anaplastic thyroid carcinoma connects JAK1/2-STAT3 suppression with DRP1 transcription, mitochondrial fission, apoptosis, and GSDME-mediated pyroptosis. This article translates those findings into a rigorous framework for pathway validation, assay design, and translational decision-making.
-
Sumatriptan Succinate: Mechanism & Research Use
2026-09-02
Sumatriptan Succinate is a selective 5-HT1 receptor agonist with established 5-HT1B/1D activity in acute migraine treatment. Its effects on CGRP release, inflammatory signaling, metabolism, and experimental injury models support carefully bounded serotonergic signaling research.
-
4-Phenylbutyric Acid in ER Stress Research
2026-09-02
4-Phenylbutyric acid (4-PBA) provides a practical chemical-chaperone strategy for testing whether endoplasmic reticulum stress contributes to toxic injury. This workflow pairs ER stress alleviation with ferroptosis, viability, and kidney-injury readouts to improve mechanistic resolution in HK-2 cell models.
-
Propranolol: Applied Research Workflows
2026-09-01
Propranolol supports translational workflows spanning cardiovascular regulation, emotional memory modulation, metabolic assays, and essential tremor research. This guide connects formulation, dosing design, TMS-based neurophysiology, and troubleshooting to practical use of SKU BA1217.
-
SW033291: 15-PGDH Inhibitor Research
2026-09-01
SW033291 is a potent 15-PGDH inhibitor that increases prostaglandin E2 in enzyme and cellular assays. Preclinical findings connect 15-PGDH inhibition with hematopoiesis stimulation, tissue regeneration research, and improved muscle repair during semaglutide-associated weight loss.